Latham & Watkins represented Agenus Inc. in the transaction. Agenus Inc. (Agenus), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Sight Sciences, Inc. in the offering, while Davis Polk advised the representatives of the several underwriters. Sight Sciences, Inc. executed its initial public...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented Senda Biosciences in the transaction. Senda Biosciences, a therapeutics platform company creating novel categories of medicines based on a new field...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented SQZ Biotechnologies Company in the transaction. SQZ Biotechnologies Company (NYSE: SQZ) (SQZ), a cell therapy company developing novel treatments for multiple...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represented the underwriters in the offering. NANO-X IMAGING LTD (NASDAQ: NNOX), an innovative medical imaging technology company, has announced that it has...
You must be a Standard 1 Year member to access this content.
